Urokinase biosimilar - Tasly Pharmaceutical

Drug Profile

Urokinase biosimilar - Tasly Pharmaceutical

Alternative Names: Recombinant human prourokinase; Recombinant human urokinase - Tasly Pharmaceuticals; rhPro-uk - Tasly Pharmaceuticals

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Tasly Pharmaceuticals, Inc.
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase II Pulmonary embolism

Most Recent Events

  • 09 May 2017 Phase-II clinical trials in Pulmonary embolism in China (IV) (NCT03108833)
  • 17 Apr 2017 Tasly Pharmaceuticals plans the ERUPTE phase II trial for Pulmonary embolism in China (NCT03108833)
  • 21 Nov 2011 Launched for Myocardial infarction in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top